Nuclear receptors (NRs) exert crucial functions in controlling metabolism and inflammation by both positively and negatively regulating gene expression. Recent evidence suggests that the transcriptional activities of many NRs can be modulated and even re-directed through post-translational modification by small ubiquitin-related modifiers (SUMO). SUMOylation triggers a plethora of diverse molecular events that can alter both the fate and function of modified NRs at the nongenomic, genomic, and epigenomic level. However, it is the intriguing link of SUMOylation to transcriptional repression, and in particular to transrepression, that has emerged as a common underlying mechanism that impacts on biological processes controlled by NRs. It further appears that the cell-type-specific SUMOylation status of NRs can be regulated by ligands and by signal-dependent crosstalk of post-translational modifications. Given the causal role of altered NR signaling in the development and pathogenesis of human diseases, it is likely that aberrant SUMO conjugation, deconjugation, or interpretation contributes to these alterations. Here, we review the current progress made in both the study and understanding of the molecular mechanisms and consequences of NR SUMOylation and also discuss the physiological and pharmacological implications with a particular focus on transrepression pathways that link metabolism and inflammation. This article is part of a Special Issue entitled: Translating nuclear receptors from health to disease.
either directly as E3 ligases or by recruiting an E3 ligase complex [10] [11] [12] [13] [14] . Whether other SUMO E3 ligases, such as the nuclear pore protein RanBP2, the polycomb group protein PC2, or members of the TRIM family of proteins, play roles in NR modification is currently unknown [15] [16] [17] [18] .
SUMOylation is a reversible and dynamic process through the action of SUMO proteases (referred to as SENP or SuPr) that function as isopeptidases to deconjugate SUMO from substrates [19] . The action of SUMO proteases at specific substrates can be influenced by intracellular signals and the cellular environment, which control and fine-tune the SUMOylation status. Appreciating SUMO deconjugation may resolve the apparent SUMO paradox, which refers to the small detectable fraction of SUMOylated proteins in vivo. It has been postulated that SUMOylation may act transient by marking proteins with a history of modification, i.e., a "SUMO memory" [7] . This concept is highly relevant for understanding the role of SUMOylation in transcriptional processes linked to NR signaling.
The SUMO acceptor lysine residues in substrates often fall within a recognizable consensus sequence [20, 21] . Most common is the classic SUMO consensus motif ψKxE (where ψ is a large hydrophobic amino acid residue and K the acceptor lysine), which is also found in many NRs (Table 1) . Variants of this motif have been recognized to function as phospho-dependent SUMO motifs (PDSM), composed of a prolinedirected phosphorylation site adjacent to the acceptor lysine [22] . PDSMs have been identified in many transcription factors including the N-terminal domains of NRs such as peroxisome proliferator-activated receptor PPARγ and estrogen-related receptors ERRs [20, 23] . Thus, PDSMs can couple phosphorylation and SUMOylation, perhaps also acetylation, to transcriptional repression. Negatively charged SUMO motifs (NDSMs) represent another extension of the consensus motif [21] . Interestingly, SUMO conjugation can also occur at acceptor lysines that are not within a recognizable consensus sequence. The exact mechanism of substrate recognition and conjugation at these nonconsensus sites remains to be clarified but may be linked to preferential modification by SUMO-2/3 [24] and the action of specific E3 ligases or modulating factors. A notable example for such a pathway is the ligandregulated conjugation of SUMO-2/3 to the ligand-binding domain (LBD) of the oxysterol receptors ("liver X" receptors) LXRs [10, 14] (discussed further below).
Crosstalk between SUMOylation and other PTMs, which can target the same acceptor site(s), is a fundamental mechanism that regulates the function and stability of substrates and whose dysregulation is linked to diverse disease states [6, 25] . Crosstalk between SUMOylation and ubiquitination or acetylation has been demonstrated, for example, to be crucial for appropriate signaling by NFκB or p53, respectively, in pathways linked to genotoxic stress and cancer [26, 27] , and needs to be further explored in NR SUMOylation pathways (see Table 1 ). Also, little is currently known about the signal-or cell-type-dependent regulation of the SUMO machinery and of NR SUMOylation. Various cellular stresses, including heat shock, osmotic stress, and reactive oxygen species, can globally affect SUMO conjugation and deconjugation, as revealed by proteomic analyses [5, 24, 28] . Whether such changes also occur in response to metabolic and pathogenic stress associated with diseases and infections remains an interesting issue to be explored. Clearly, there are already indications that dysregulated SUMO conjugation contributes to the pathogenesis and development of cardiovascular and autoimmune diseases [6, 29, 30 ].
Signal-dependent transcriptional regulation by NRs
NRs are signal-regulated transcription factors that exert diverse and crucial biological functions in pathways governing developmental, reproductive, metabolic, and inflammatory processes [31] [32] [33] [34] [35] . In most of these processes, the primary function of NRs is to regulate gene expression at the transcriptional level in response to cellular signals. Coregulators have been recognized to be crucial components of NR signaling since they are necessary to facilitate specific epigenomic modifications such as histone (de-) acetylation and (de-) methylation, as well as nucleosome remodeling. Coregulators usually act downstream in the activation cascade by associating with DNA-bound NRs. However, recent findings on ER and LXR signaling also point at crucial functions of Fig. 1 . The NR-SUMO cycle: conjugation, interpretation, de-conjugation. NR SUMOylation is facilitated by an enzymatic cascade that involves three classes of enzymes: a heterodimeric E1 activating enzyme SAE1/2, a single E2-conjugating enzyme UBC9, and various E3 ligases (e.g., PIAS family members, HDAC4). NR SUMOylation is "interpreted" by diverse cellular effectors, i.e., proteins that employ SUMO-interaction motifs (SIMs) to recognize the modification and then to trigger subsequent molecular events. Suspected transcriptional effectors are SIM-containing subunits (e.g., CoREST, ARIP4, GPS2) of diverse corepressor (CoR) complexes linked to repressive histone modifications (e.g., deacetylation). NR SUMOylation is reversed through the action of SUMO proteases/isopeptidases (SuPr, SENP) that deconjugate SUMO from NRs. Both SUMO ligases and proteases can function in a cell-type, NR-, and SUMO (Su-1/2/3)-specific manner. De-SUMOylation is necessary for turnover and degradation of NRs and SUMO components but may also occur rapidly and transiently, thereby precluding SUMO interpretation and causing an apparent lack of functional effects. During the cycle, NRs adopt distinct conformational and functional stages, i.e., apo (inactive, unliganded), holo (activated, liganded), and sumo (modified, unliganded, or liganded).
coregulators (e.g., histone methylases, demethylases and GPS2) and epigenomic modifications (e.g., histone 3 lysine 9 methylation) in facilitating ligand-dependent NR recruitment to specific genomic loci [36, 37] .
NRs have employed a variety of molecular strategies regarding their ability to sense and transmit signaling inputs into coregulator-dependent transcriptional responses. Many conventional NRs appear capable of directly binding to small-molecule ligands (e.g., steroid hormones, lipids, Abbreviations: SUMO sites: A -atypical SUMO motif(s), C -SUMO consensus motif (ψKxE), P -phospho-dependent SUMO motif (ψKxExxS/T), L -ligand-enhanced; NR-domains: NTD -N-terminal domain, DBD -DNA-binding domain, Hinge -hinge region, LBD -ligand-binding domain; SUMO machinery: Su -SUMO, PIAS -protein inhibitor or activated STAT, HDAC -histone deacetylase, SIM -SUMO interaction motif.
xenobiotics, synthetic drugs). Ligand-binding has direct consequences on NR activity as it induces conformational changes that cause NRs to associate with distinct sets of coregulators. Traditional models envisage that agonists drive transcriptional activation by promoting the recruitment of NR coactivators, i.e., SRC1/2/3 and p300/CBP linked to histone acetylation, ASC2/RAP250 linked to histone methylation, and the mediator subunit MED1/TRAP220 linked to RNA polymerase II [31] . In contrast, unliganded NRs, antagonists, or inverse agonists are usually connected to transcriptional repression by promoting the recruitment of corepressors such as N-CoR/SMRT and GPS2 linked to histone deacetylase (HDAC) complexes [38] . NR activity can also be regulated by cellular concentration-dependent interactions with coregulators whose expression is dynamically regulated by diverse signals. Well-established are the metabolic roles of the ligand-inducible corepressor and orphan receptor SHP ("small heterodimer partner", NR0B2) [39] or of the cAMP-inducible coactivator PGC-1α [40] . This strategy seems in particular crucial to regulate the activity of some orphan NRs that cannot be directly regulated by ligands. The activity of potentially every NR can be regulated by PTMs, which is traditionally viewed as a way to achieve "ligand-independent" regulation. This may hold true for orphan receptors, but in case of ligand-regulated NRs, it has become clear that ligand-binding also impacts on the PTM status. (De-) phosphorylation of NRs appears to be linked both to transcriptional activation [41] , for example, in response to epidermal growth factor signaling in ER-positive breast cancer cells [42] , or to repression, for example, in response to fibroblast growth factor 15/19 signaling in hepatocytes [43] . An increasing number of studies begin to address the role of additional PTMs in NR signaling, such as acetylation, methylation, glycosylation, ubiquitination, and SUMOylation [44] [45] [46] [47] [48] .
Finally, NRs are capable of transcriptional crosstalk with a number of other signaling pathways. For example, negative crosstalk between the glucocorticoid receptor (GR) and NFκB signaling underlies the clinical application of how synthetic glucocorticoids inhibit inflammatory processes [49, 50] . Direct interactions of primary transcription factors are presumed to trigger a genomic tethering mechanism by which GR is recruited to DNA-bound NFκB. Intriguingly, more recent work has identified negative crosstalk pathways linked to the antiinflammatory action of various lipid-activated NRs that appear to depend on SUMOylation-dependent tethering to corepressor complexes at inflammatory genes [10, 14, 33, 35, 51] . Current progress in analyzing the molecular events that govern this SUMO-mediated crosstalk, commonly referred to as transrepression, will be discussed in more detail below.
Discovery of NR SUMOylation
In a historical perspective, it is interesting to note that it was the search for coregulators that led to the identification of components of the SUMO machinery as NR-associated proteins. For example, the human homologue of yeast UBC9 was identified in yeast two-hybrid screens as a GR-associated protein [52] before its role as a SUMO E2-conjugating enzyme was uncovered. Similarly, members of the PIAS family of SUMO E3 ligases were originally identified and characterized as potential coactivators of androgen receptor (AR) and additional steroid receptors [53] . These studies implied that components of the SUMO machinery modulate NR transcription, although the direct link to NR SUMOylation was not established at that time. Indeed, there are some indications that PIAS proteins can function as coregulators without triggering NR SUMOylation [53] . UBC9, SUMO E3 ligases, and SUMO proteases were found to associate with a variety of NRs, which often initiated subsequent investigations of NR SUMOylation (Table 1) . Evidence for site-specific conjugation of SUMO to a NR was provided first for AR, along with the demonstration that PIAS proteins function as SUMO E3 ligases [54] . Interestingly, the AR SUMO consensus site appears to be conserved in other steroid receptors and overlaps a transcriptional synergy control motif in the N-termini of these NRs. AR plays major roles in regulating the transcription of genes triggering prostate cancer cell proliferation, both androgen-dependent and androgen-independent, and the role of SUMOylation in these pathways is the subject of intense investigations, as reviewed elsewhere [47, 53] .
Molecular consequences of NR SUMOylation
Because the major function of NRs is to act as gene-specific transcriptional activators and repressors, many studies analyzing NR SUMOylation have focused on its role in transcription. Only in very few instances does SUMO modification correlate with increased transcriptional activity, as reported for the orphan receptor RORα [55] . In most described cases, SUMO modification clearly inhibits the transcriptional activity of the modified NR and even triggers "active" repression (Table 1) , consistent with related observation made with other transcription factors [56] [57] [58] .
A variety of different inhibitory mechanisms are postulated to be a consequence of NR SUMOylation (Fig. 2 and Table 1 ).
SUMOylation was early observed to trigger intranuclear localization changes of the modified NRs. Translocation into a particular subnuclear domain such as PML bodies or nuclear speckles has been reported for liver receptor homologue LRH-1, steroidogenic factor SF-1, and testicular receptor TR2 [59] [60] [61] [62] . Whether PML-associated SUMOylated NRs are bound to chromatin in vivo and thus capable of active repression, or whether PML bodies serve as a "storage" compartment, remains an interesting issue for further investigations.
Different types of synergistic or antagonistic PTM crosstalk can cause -or contribute to -several inhibitory mechanisms. Observations made with many non-NR substrates revealed that SUMOylation can antagonize ubiquitination and thereby inhibit proteasomal degradation [63] . Since degradation-dependent turnover has been recognized to be necessary for transcriptional activation of ERα, which is a target for SUMO modification [64] , SUMOylation would result in transcriptional inhibition. A related mechanism may apply to the LXRs, crucial regulators of lipid, and glucose metabolism in a number of tissues. Inferred from data of different studies, SUMOylation, ubiquitination, and acetylation appear to target a conserved acceptor lysine residue adjacent to the LBD helix 12, the modification of which could be dynamically regulated by ligands and other signals [10, 14, 65] . With regard to metabolic consequences, it is an interesting possibility that inhibition of LXRα transcription by elevated SUMOylation would decrease its lipogenic activity in liver [65] . Another type of PTM antagonism was reported for steroidogenic factor SF-1, where SUMOylation inhibited phosphorylation of an acceptor lysine-adjacent serine residue within a phosphorylation-dependent activation domain [66] . In contrast, transcriptional repression of ERR α and γ is mediated by phosphorylationdependent SUMOylation of a synergy control motif within the N-terminal activation domain [23, 67] .
Intriguing are indications that SUMOylation may prevent some NRs from efficiently dimerizing with retinoic acid receptors (RXRs), a pre-requisite for direct DNA-binding and thus transcriptional activation of all RXR heterodimers. This potentially fundamental inhibitory mechanism of remarkable simplicity emerged from our recent study on the role of LXR SUMOylation in controlling liver inflammatory (acute phase response) gene expression [14] . When analyzing the promoter recruitment of SUMOylated LXRs by chromatin immunoprecipiation (ChIP) assays combined with RNA interference-mediated depletion of SUMOs or UBC9, we observed that RXR was not recruited to these SUMOdependent loci, although it was recruited together with LXR to classic LXR/RXR target genes. In support of this possibility, molecular modeling suggests that one of the putative SUMO acceptor lysines in human LXRβ (K410) is located in close proximity to the RXR heterodimerization surface within the LBD (E.T., unpublished observation). While a future validation of the generality of this mechanism is necessary, it is notable that additional heterodimeric NRs can be SUMOylated within this LBD region, for example, PPARs [51, 68] .
SUMOylation may also directly modulate or inhibit DNA-binding of both NR monomers and dimers. This has been characterized in case of SF-1, where DNA-binding and SUMOylation at sites adjacent to the DNA-binding domain occurred mutually exclusively [69] . The study suggested that SUMOylation of SF-1, and perhaps of other NRs, impairs recognition of a subset of SUMO-sensitive target genes. Since LRH-1 (NR5A2) is the closest homolog to SF-1 (NR5A1) and can be SUMOylated at conserved sites, it will be interesting to analyze the effect of SUMOylation on LRH-1 binding to target genes. Indeed, our preliminary data suggested that the expression of the hepatic LRH-1 target genes shp and cyp7A1 was enhanced in SUMO-1 knockout mice, which was related to elevated LRH-1 recruitment to the promoters of these genes [14] . Concerning the physiological implications, SUMOylation of SF-1 is expected to impact on steroidogenic gene expression in the gonads and in the adrenal. Additionally, SF-1 controls crucial metabolic pathways via its action in the ventromedial hypothalamus (VMH), possibly by communicating with leptin signaling [70, 71] . In contrast, LRH-1 SUMOylation may have an impact on inflammation, lipid and glucose metabolism in liver and intestine, and on steroidogenesis in the gonads. Intriguingly, both LRH-1 and SF-1 can transcriptionally re-program somatic cells into pluripotent stem cells, which in the case of LRH-1 requires SUMOylation [72] .
Evidence has accumulated that SUMOylation triggers direct transcriptional repression mechanisms, referred to as "active repression". Central to current models is the idea that SUMOylation changes the interactions of transcription factors such as NRs with numerous coregulators. Dissociation of coactivators may be one possible inhibitory mechanism, for example, in cases where SUMOylation occurs within -or adjacent to -the transcription activation domains of NRs. Much more common, however, appears that SUMOylation generates new interaction surfaces at NRs (including at ligand-activated NRs that typically are not associated with repression) that recruit corepressor complexes involved in active repression. Indeed, proteomic and targeted approaches have already revealed a number of SUMO-binding corepressors linked to histone deacetylation, (de-) methylation, and other chromatinmodifying complexes [14, [73] [74] [75] [76] . SUMO recognition and binding, i.e., non-covalent interaction with SUMO, appear the common key feature of these factors and led to the identification of SUMO interaction motifs (SIMs) [77] . The classic SIM consensus consists of a hydrophobic core (I/V-x-I/V-I/V or I/V-I/V-x-I/V)) flanked by acidic residues and is implicated in the binding of all three SUMO isoforms. Variations in the consensus sequence, including SUMO subtype-specific motifs, have been identified [74] with different types of SIMs awaiting future identification. Examples of SIMcontaining NR corepressors include (i) Daxx, demonstrated to repress SUMOylated GR in conjunction with HDAC2 [78] ; (ii) CoREST, demonstrated to recruit the histone demethylase LSD1/ KDM1 to SUMO-2/3 substrates and known for its link to HDACs and to NRs [74, 79] ; (iii) ARIP4, purified as partner of SUMOylated SF-1 and demonstrated to interact with modified LRH-1, GR, and AR [76] ; and (iv) GPS2, a stoichiometric subunit of the N-CoR/HDAC3 corepressor complex, which attracts SUMOylated LRH-1 and LXRβ Fig. 2 . Molecular consequences of NR SUMOylation. SUMOylation triggers a plethora of molecular events that depend on the modified NR, including its ligand and coregulator status, the location of the SUMO acceptor lysine(s) within an NR, the affinity of a given NR to UBC9 and specific E3 ligases, and diverse cell-type-specific modulators. Abbreviations are as in Fig. 1 , except NRE: NR-response elements, direct genomic binding sites. PML: component of a multiprotein complex termed nuclear PML bodies/oncogenic domains, originally discovered in patients suffering from acute promyelocytic leukaemia (APL), effector that recognizes SUMOylated proteins via SIMs. PTM: post-translational modifications such as ubiquitination, acetylation, methylation, all with the potential to target the same SUMO acceptor lysine(s), and phosphorylation.
during anti-inflammatory transrepression in the liver [14] , as discussed further below.
SUMO-dependent NR transrepression pathways that link metabolism and inflammation
Work over the last decade has identified negative crosstalk mechanisms, referred to as transrepression, that are linked to the anti-inflammatory actions of various NRs in macrophages and other cell-types of the immune system [33] [34] [35] 50, 80] . The academic and pharmaceutical interest in these pathways is not limited to classic inflammatory diseases, such as those targeted by anti-inflammatory glucocorticoids [81] , as inflammatory processes have emerged as key players in the development of metabolic diseases such as diabetes, atherosclerosis, and obesity [80, 82] . A number of significant studies suggest crucial roles for numerous lipid-activated NRs in linking lipid metabolism to inflammatory processes and disease [83] [84] [85] [86] [87] [88] . These NRs include PPARs -receptors for fatty acids, LXRs -receptors for oxysterols and other cholesterol metabolites, and LRH-1, a putative receptor for phospholipids.
Efforts to understand the underlying molecular mechanisms indicated that lipid-activated NRs, apparently similar to GR, inhibit inflammatory gene transcription by interfering with the activities of pro-inflammatory transcription factors such as AP-1, NFκB, or C/EBPs. Although the resulting repression is promoter-specific, it does not appear to involve direct NR DNA-binding to NR response elements, suggesting a tethering mechanism known as transrepression [10, 14, 51] . Interestingly, the transrepression mechanism of PPARγ and LXRs appears to be distinct from the GR mechanism [50, 87, 89] . Although it was thought to be the involvement of corepressors in the PPAR/LXR mechanism that caused these differences, it was the link to NR SUMOylation that began to resolve this issue. Glass and coworkers clearly demonstrated that ligand-induced SUMOylation of the LBD was critical for tethering liganded PPARγ or LXRs to inflammatory promoters in macrophages, which then prevented signal-induced removal of the corepressor complex from these promoters [10, 51] .
What remained unresolved was the specific mechanism of how agonist-bound and SUMOylated NRs would recognize the corepressor complex [13] . A study from our laboratory has addressed this issue and led to the identification of the corepressor complex subunit GPS2 as one likely molecular target of SUMOylated NRs in the SUMOdependent transrepression pathway [14] . GPS2 was initially identified biochemically by Roeder and coworkers [90] and independently by means of two-hybrid interaction screens in our laboratory [91] . We then demonstrated that GPS2 functions in both cholesterol metabolism, via coregulating LRH-1 and the bile acid receptor FXR in the liver, and in cholesterol transport, via coregulating LXRs in macrophages [37, 92] . In our recent study, we investigated the potential role of these receptors, their synthetic ligands, and their coregulators, in inhibiting inflammatory gene expression in the liver during the acute phase response (APR). A key result was that liver transrepression by LXR and LRH-1 occurred via the same SUMO/corepressor pathway that was previously identified in macrophages. We could further demonstrate that (a) GPS2 is associated with the corepressor complex at APR promoters, (b) GPS2 depletion results in the lack of NR-SUMO docking and transrepression (both in hepatocytes and in macrophages), (c) GPS2 directly interacts with agonist-bound NRs, and (d) GPS2 interacts with free and NR-conjugated SUMOs (via a putative SIM region in its N-terminus). Our proposal that GPS2 acts as a transrepression mediator clarifies the apparent paradox of how ligandactivated NRs can bind to the N-CoR corepressor complex at inflammatory genes. The peculiar NR-SUMO binding feature of GPS2 appears to distinguish it from other subunits of the corepressor complex, some of which are likely to further specify the SUMO targeting mechanism. However, it is perhaps this unique capability of GPS2 to recognize also "free", i.e., non-SUMOylated liganded NRs, that pre-disposes GPS2-NR complexes to rapidly enter the corepressor complex-depending transrepression pathway in response to reversible and dynamic SUMOylation cycles.
Open issues to be addressed
Of interest is to define the molecular features that enable SUMOylated NRs to selectively enter the transrepression pathway but possibly prevent them from conventional activation. The application of transrepression-selective ligands could be one way to achieve this (discussed further below), the interference with RXR heterodimerization, another way. Indeed, ChIP assays have suggested that LXR acts without RXR in the liver transrepression pathway in comparison to activation pathways where LXR heterodimerizes with RXR [14, 37] . Inhibition of RXR heterodimerization by SUMOylation not only would exclude SUMOylated NRs from classic activation pathways but could also be a way of generating pools of modified NRs available for the transrepression pathway. Since SUMOylation is a reversible and dynamic process susceptible to deconjugation by isopeptidases, only a small fraction of SUMOylated NRs might be detectable in vivo. Future studies of the ratio of free versus SUMOylated NRs and of their promoter recruitment upon knockdown of SUMO proteases may further address this issue.
It remains also enigmatic why some NRs are preferentially modified by a specific SUMO subtype and what the consequences of this subtypespecific modification may be. As inferred from published studies, it seems that PPARγ, LRH-1, and other NRs (Table 1) are modified by SUMO-1 at acceptor lysine(s) within the classic consensus sequence ψKxE, while LXRβ and the orphan NR ("nuclear receptor-related") NURR1 are modified by SUMO-2/3 at non-consensus sites. Whether this is due to the specific involvement of HDAC4, other SUMO-2/3-selective E3 ligases or additional modulators of SUMOylation, is currently unknown. Notably, HDAC4 is known to respond to intracellular signals such as phosphorylation, which may influence its E3 activity, intracellular localization, or turnover.
The LXR studies suggest that the extent of SUMOylation for each subtype and the choice of preferred acceptor lysine residues seem to be influenced by the cellular environment and/or the experimental conditions of analysis. In macrophages, both LXR subtypes appear to be modified by SUMO-2, consistent with both SUMOylated LXRα and LXRβ to trigger the transrepression pathway [10] . In liver, however, only LXRβ appeared significantly modified by SUMO-2, consistent with the specific requirement of LXRβ for transrepression in human primary hepatocytes and in mouse liver in vivo [14] . The reason LXRα is not SUMOylated in liver remains unclear but could be related to the fact that some acceptor lysines are not conserved between the LXRs. Alternatively, a liver-specific SUMO protease activity or PTM antagonism may cause the difference. Indeed, one of the two SUMO acceptor lysines within the LXRα LBD appears subject to reversible acetylation/ ubiquitination cycles during metabolic gene transcription in liver [65] . To complicate matters further, different SUMOylation events have been described for LXRs during the inhibition of interferon-stimulated STAT1-signaling in brain astrocytes [93] . Here, LXRβ was modified by SUMO-1 and PIAS at a unique consensus site in the N-terminus, while LXRα was, as in macrophages, modified by SUMO-2 and HDAC4. Possibly, direct interactions of LXRs with STAT1 modulated the specificity of SUMOylation, in addition to other cell-type-specific factors. What can be concluded from these examples is, first, that NRs utilize alternative and highly cell-type-specific strategies to ensure signal-or ligand-dependent SUMO modification, and second, that we are still far from understanding the underlying molecular mechanisms.
Regarding the transcriptional consequences of selective SUMOylation, it is conceivable that subtype-specific SUMO binders such as CoREST [74] or specific SUMO proteases play distinctive roles in differentiating the responses. However, most of the currently known SUMO-binding proteins including PIAS E3 ligases, SUMO proteases, and the corepressors GPS2 and ARIP4 appear to recognize modified NRs irrespective of the SUMO subtype. Additional open questions concern the mechanisms by which the two related corepressors N-CoR and SMRT, both are implicated in assembling the core complex containing GPS2 and TBL/TBLR1 [90] , specify the transrepression pathway in a cell-type-dependent manner. In macrophages, both N-CoR and SMRT appear to be required for LXR transrepression at most inflammatory genes, although some genes were selectively dependent on only one of the two corepressors [94] . In contrast, key inflammatory APR genes in liver that were transrepressed by LXR seemed to require N-CoR but not SMRT, together with GPS2 and additional shared subunits of the corepressor complex [14] .
Implications for human diseases and potential therapeutic applications
The dual control of metabolic and associated inflammatory pathways via the same NR(s), and often the same ligand(s), has direct implications for our understanding and the future pharmacological management of metabolic and inflammatory diseases. A major therapeutic concept would be to identify ligands that differentially modulate the activation, active repression, and transrepression functions of NRs, in order to achieve a safer and more specific targeting of pathogenic processes. This concept proposes ligand-specific distinct NR conformations, inducing regulatory surfaces that specifically trigger SUMOylation and GPS2 docking, to facilitate the identification of pathway-selective ligands. We suggest that the term "selective NR SUMO modulators" (SSMs) would be appropriate for such future compounds (Fig. 3) .
In the case of LXRs and probably other metabolic NRs, a variety of pharmacologic strategies for how to develop compounds with improved subtype and pathway selectivity have been proposed [95] [96] [97] . New types of selective LXR modulators such as LXR antagonists or LXRβ agonists may allow pharmacological intervention to improve reverse cholesterol transport and anti-inflammatory activities in macrophages and liver without affecting undesired hepatic lipogenesis [95, 98] . These examples, together with the documented LXRβ-selectivity of SUMOylation and transrepression [14] , suggest that it might be possible to develop such compounds. The case of LRH-1 exemplifies that certain orphan receptors can be adopted for pharmacological development. Synthetic ligands such has cis-bicyclo[3.3.0]-oct-2-enes [99] may not only affect metabolic pathways linked to cholesterol metabolism but also potently inhibit inflammatory gene expression in the liver [14] and potentially in the intestine [100] . Since LRH-1, unlike LXRs, is not expressed in macrophages and more limited to the enterohepatic axis, targeting LRH-1 would perhaps improve the tissue-selectivity of pharmaceutical strategies.
A particular area of future drug applications may be the pharmacological inhibition of the inflammation by selectively activating SUMO-dependent NR transrepression pathways in liver and potentially additional tissues and cell types. Elevated levels of acute phase proteins, such as those associated with infections and metabolic diseases, may alter the composition of high-density lipoprotein (HDL) particles, e.g., depletion of ApoA1 and enrichment of haptoglobin and serum amyloid A (SAA) to generate acute-phase HDL. Acute-phase HDL is believed to be pro-atherogenic as it cannot protect against low-density lipoprotein (LDL) oxidation and thus does not reduce macrophage foam cell formation [101] . In addition, epidemiologic studies suggest a greater risk of coronary artery disease in subjects with high levels of acute phase proteins [102] .
Notably, the liver is not the only source of acute phase proteins and thus not the only site for pharmacological intervention with NR drugs. For example, plasminogen activator inhibitor-1 (PAI-1), haptoglobin, and SAA are also synthesized in white adipocyte tissue of obese subjects, Fig. 3 . Putative NR-SUMO-regulated disease pathways that imply future therapeutic applications. Highlighted are some intriguing examples of NRs, tissues, and diseases, where SUMOylation-dependent NR pathways, in particular transrepression, might occur. Included are only the NRs that already have been experimentally demonstrated to be SUMOylated (Table 1) . Future therapeutic approaches may employ drugs that function as "Selective NR SUMO Modulators", which would represent a conceptually new category of synthetic NR compounds.
presumably in response to adipokines and cytokines from adiposeassociated macrophages [103] . Intriguingly, it has been reported that adipocyte-derived acute phase proteins may influence cholesterol efflux [104] , emphasizing the interplay of lipid metabolism and inflammatory processes in various metabolic disease pathways. In light of these observations, it will be important to determine to what extent SUMOmediated transrepression pathways play roles in adipocytes and obesity. Indeed, corepressor complexes (containing GPS2 and N-CoR/SMRT) can be detected at inflammatory genes in human adipose tissue of normal and obese subjects (N.V., unpublished data). Considering that clinical treatment of type-2 diabetic obese patients with PPARγ agonists (TZDs, thiazolidinediones, glitazones) appears to reduce adipose tissue inflammation [80, 96, 105] , it is tempting to speculate that PPARγ controls inflammation in adipocytes, as in macrophages, by the transrepression pathway.
8. Future perspectives: NR-SUMO pathways within physiology and disease are expanding Considering current progress in characterizing SUMO-NR pathways, it is likely that substantially more SUMO-dependent NR pathways will be uncovered. A large number of NRs can be SUMOylated (Table 1) , many of which are already implicated in regulating metabolic and inflammatory pathways in a variety of tissues (Fig. 3) . For example, recent evidence points at protective functions of LRH-1 and FXR in mouse models of intestinal inflammation, suggesting an involvement of these NRs, and their respective ligands, in the pathogenesis of human inflammatory bowel diseases [100, 106] . Whether or not these anti-inflammatory actions depend on NR SUMOylation in the intestine remains a challenging task to address. Also, gender-dependent steroid hormone signaling is assumed to differentially modulate inflammatory processes linked to cardiovascular disease, osteoporosis, liver cancer, neurodegenerative, and autoimmune diseases [48, [107] [108] [109] [110] . Steroid receptors are established SUMO substrates and may (trans-) repress via direct crosstalk but also via SUMO-dependent mechanisms, another interesting aspect to address. Surprisingly, largely unexplored are the molecular and physiological consequences of NR coregulator SUMOylation (some examples are given in Table 1 ) that could play equally important roles in modulating and redirecting NR pathways.
Evidently, studies in the past have already indicated that SUMOylation potentially affects every possible aspect of NR function, including many NR-regulated metabolic and inflammatory processes. Therefore, the focused molecular and physiological characterization of these processes is of immense relevance for the understanding and pharmacological management of human metabolic and inflammatory diseases. One priority of future research should be to expand the experimental repertoire for analyzing NR SUMOylation by disease mechanism-oriented in vivo approaches. Such approaches may include diverse mouse models that are defective for a specific component of SUMO modification (e.g., SUMOs, SUMO ligases and proteases, NR acceptor lysine mutants) or SUMO interpretation (e.g., GPS2, CoREST, SIM mutants). These models will not only reveal new insights into mechanisms and consequences of SUMO function, they will also be invaluable tools to test future synthetic ligands that as SSMs specifically modulate NR SUMOylation. Equally importantly, genomic, epigenomic and proteomic approaches should aim to identify those components of the SUMO modification and interpretation machinery that are altered in human disease states. Certainly, these and many other possible future investigations will be necessary to fully establish and appreciate the role of SUMOylation in NR pathways governing physiology and disease.
